Navigation Links
A potential route for human tumor gene therapy
Date:5/20/2008

The type 1 Na+/H+ exchanger (NHE1) is a transmembrane protein found in all eukaryotic cells. One of its functions is to evacuate excessive H+ in the cytoplasm by means of Na+-H+ exchange, resulting in stable intracellular pH value. Inhibition of the upregulation of NHE-1 gene expression in human gastric carcinoma cells can induce intracellular acidification, resulting in apoptosis of tumor cells, which is helpful for the treatment of tumors.

This study, performed by a team led by Professor Hai-Feng Liu, is described in a research article to be published on April 14, 2008 in the World Journal of Gastroenterology.

Previous studies have proven that the significantly higher expression level of NHE1 protein in gastric carcinoma tissues than in normal gastric tissues is closely associated with the genesis and progression of tumors, suggesting that NHE1 can be used as the target in treatment of tumors. However, further studies are needed to know whether the intervention of the antisense NHE1 gene can decrease type 1 Na+/H+ exchange of membranous ion exchange protein in gastric carcinoma cells, and the effects on the biological behaviors of gastric carcinoma cells.

The purpose of transfection of the antisense NHE1 gene into the human gastric carcinoma cell line SGC-7901 is to investigate the effects of antisense therapy targeting the NHE1 gene on the malignant phenotypes of gastric carcinoma cells. The results indicate NHE1 genes are among the important genes in maintaining the phenotypes of the SGC-7901 cell line. NHE1 might be closely associated with the malignant biological behaviors of tumor cells, so the phenotypes of the tumor will be restrained when NHE1 is inhibited.

This is an interesting article examining the effect of inhibiting NHE1 on tumor survival. It would be useful to make clearer in the abstract what NHE1 is. Further research should be done on gene therapy for gastric carcinomas.


'/>"/>

Contact: Jing Zhu
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. High Growth Potential for Carotid Stent and Thoracic Aortic Stent Graft Markets
2. Phase 3 GATTEX results presented at DDW highlight potential new treatment in short bowel syndrome
3. Estimated 3.2 million Burmese potentially affected by cyclone
4. Most Baby Boomers are Financially Unprepared for a Potential Disability
5. New report: Arthritis is a potential barrier to physical activity for adults with diabetes
6. Improving anxiety treatment through the help of brain imaging: A potential future treatment strategy
7. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
8. Study: Casual Video Games Demonstrate Ability to Relieve Stress, Improve Mood: Potential Clinical Significance Highlighted
9. Potential viral therapy weapon for difficult cancers is safe and effective in study
10. Penn researchers find potential in yeast for selecting Lou Gehrigs disease drugs
11. Minnesota partnership advances potential MS therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2008)...an farm, FDA announces , , FRIDAY, July...ering the first big clue in the nationwide salmone...ay that tainted jalapeno peppers had been definiti...d and Drug Administration gave the all-clear to ja...tes, but warned consumers to avoid any raw jalapen...
(Date:7/25/2008)...ter & Olsen LLP has filed a,class action lawsuit a...,"Company") (Nasdaq: ARTC ) and certain of its of...District of Texas on behalf of all persons or,enti...m January 24, 2008,through July 18, 2008 (the "Com... or entities who purchased call options or sold pu...
(Date:7/25/2008)...inancial results -, LAVAL, QC, July 25 /PRNewswir...DSS) today announced that it will host a conferenc...scuss its second quarter 2008,financial results. L...cial,results via news release at approximately 7:0...ll by telephone, dial 416-646-3095 or,1-800-814-48...
(Date:7/25/2008)...FirstCall/ -- Thoratec,Corporation (Nasdaq: THOR ...atory support therapies to save, support and resto...port its operating results for the second,quarter ...uly 31., The company will hold a conference call ...ivities to all interested parties at 1:30 p.m.,Pa...
Breaking Medicine News(10 mins):Health News:Mexican Peppers ID'd as Salmonella Culprits 2Health News:Mexican Peppers ID'd as Salmonella Culprits 3Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 2Health News:Klafter & Olsen LLP Announces That It Has Filed a Class Action Lawsuit Against ArthroCare Corporation on Behalf of Common Stock Holders and Certain Traders in ArthroCare Options 3Health News:Labopharm to host conference call Friday, August 8, 2008 at 8:30 A.M. (ET) 2Health News:Thoratec Schedules Second Quarter 2008 Conference Call, Webcast 2
...rnment is likely to invoke the compulsory licensin...ble domestic drug //firms to produce and stockpile...seful in combating the global threat against the m... 92 empowers the government to issue CL without re...
...l wall hernias are one of the most common conditio...,000 repairs// performed annually. Although ventra...rences and complications remain a vexing problem. ... consistent risk factor for recurrence after VHR. ...
...Paxton and Colleagues from University of Amsterdam...nt transmission of HIV infection to child. Though ...on of HIV accounts for a large proportion of HIV i...sult of breastfeeding, which requires transfer of ...
... cancer patient made the journey from London to In...cation-Herceptin.// India is likely to attract mo...ving both for surgical procedures and medication.F...ate hospital in Pune for a mastectomy and reconstr...
Other Medicine News:Health News:Predictors Of Wound Infection In Ventral Hernia Repair 2Health News:Breast feeding can prevent HIV infection transmission 2
(Date:7/23/2008)...Newswire-FirstCall/ -- Dendreon Corporation,(Nasda...ependent Data,Monitoring Committee (IDMC) to revie...survival relating to the Company,s Phase 3 IMPACT ...nt, also known as D9902B) clinical trial,of PROVEN...vestigational,active cellular immunotherapy for th...
(Date:7/22/2008)...sults from a multi-center 293-patient European, t... Exchange Symbol: CYT, MONTREAL, July 22 /PRNewsw...e global leader in cryotherapy products to treat c...reviously presented from three,European study cent...(R),were published earlier today in the Journal o...
(Date:7/22/2008)...scuss Development Plan Completed Successfully, DU...marin Corporation,plc (NASDAQ: AMRN ) today annou...at the U.S. Food and Drug Administration (FDA) to ...the treatment of,hypertriglyceridemia. Following t...se 3 with AMR101 in hypertriglyceridemia., Dr. De...
(Date:7/22/2008)...g Lantus(R) and Apidra(R) Resulted in Significant,...s, Whatever the Algorithm ...wire/ -- Results from the "Adjust to,Target in Typ...Carbohydrate,Counting for Adjustment of Mealtime I...rican Diabetes Association,s (ADA) medical journal...
Breaking Medicine Technology:Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 2Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 3Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October 4CryoCath Arctic Front(R) Results Published in JACC 2CryoCath Arctic Front(R) Results Published in JACC 3Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 2Amarin Proceeding to Phase 3 With AMR101 for Hypertriglyceridemia 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 2Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 3Newly Published Study Results Showed That Two Mealtime Insulin Dosing Algorithms Were Effective for Patients with Type 2 Diabetes 4ViroPharma to Present at Two Upcoming Healthcare Conferences 1898 1ViroPharma to Present at Two Upcoming Healthcare Conferences 1898 2Story ideas from the Journal of Biological Chemistry 1304 1Story ideas from the Journal of Biological Chemistry 1304 2Serum carcinoembryonic antigen level can reflect adrenal adenoma 6784 1Serum carcinoembryonic antigen level can reflect adrenal adenoma 6784 2Proposal to step up cardiovascular disease research 1299 1Proposal to step up cardiovascular disease research 1299 2
...asound Demonstrates Utility in Evaluating Drug,Eff...ntial for HDL,Therapy , ,PLEASANTON, CA, Mar 30, 2... Sciences, Inc. (NASDAQ: LIPD) Dr. H. Bryan Brewer..., Inc., concluded from,the wide range of presentat...(ACC) Meeting in New Orleans that the rationale fo...
...e Astellas Commitment to Overcoming Critical,Short... April 02, 2007 /PRNewswire/ --Study results,prese...robiology,and Infectious Diseases (ECCMID) show th...icafungin, both have the potential,to meet a signi...pital-acquired infections (HAIs). , Hospital-acqui...
Other Medicine Technology:Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 2Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 3Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 4Presentations at American College of Cardiology Meeting Highlight,New Opportunities for HDL Therapy 5Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease 2Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease 3Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease 4Data on Telavancin and Micafungin Hold Promise of New Therapeutic,Options in Fight Against Serious Infectious Disease 5
Smooth colibri tip; In Titanium.
Fine .12mm Tip With 5mm Platform; In Titanium.
Curved Shaft with 5mm Platform; 1x2, 0.12 mm teeth; In Titanium.
0.3mm tips; 9.5mm from tips to cross action; in Titanium.
Medicine Products: